NDA 020971 · Deproco
Septocaine
Articaine Hydrochloride, Epinephrine Bitartrate · Injection
NovelLast checked: Nov 19, 2026Latest source record: Nov 2, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2000
Apr 3, 2000
Approved uses
1
Original approval plus efficacy supplements
Registered trials
109
13 Phase 3, 2 recruiting
FAERS reports
600
155 serious, 9 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Mar 26, 2026.
Articaine HCl and Epinephrine is indicated for local, infiltrative, or conductive anesthesia in both simple and complex dental procedures in adults and pediatric patients 4 years of age or older. Articaine HCl and Epinephrine is a combination of articaine HCl, an amide local anesthetic, and epinephrine, a vasoconstrictor, is indicated for local, infiltrative, or conductive anesthesia in both simple and complex dental procedures. in adults and pediatric patients 4 years of age or older.
Mechanism: Articaine HCl is an amide local anesthetic. Local anesthetics block the generation and conduction of nerve impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse, and by reducing the rate of rise of the action potential. In general, the progression of anesthesia is related to the diameter, myelination, and conduction velocity of the affected nerve fibers. Epinephrine is a vasoconstrictor added to articaine HCl to slow absorption into the general circulation and thus prolong maintenance of an active tissue...
Therapeutic areas: Kidney and urology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 3, 2000 Original approval · Type 1 - New Molecular Entity and Type 4 - New Combination NovelLetterLabelReview
2 products under this application
- SEPTOCAINE · ARTICAINE HYDROCHLORIDE 4%; EPINEPHRINE BITARTRATE EQ 0.0085MG BASE/1.7ML (4% · INJECTABLE, INJECTION · Prescription
- SEPTOCAINE · ARTICAINE HYDROCHLORIDE 4%; EPINEPHRINE BITARTRATE EQ 0.017MG BASE/1.7ML (4% · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Articaine" as an intervention, any sponsor and status, largest first.
Vanderbilt University Medical CenterAcademic, hospital or other
NCT02726620 · 22,435 participants · Start Jan 5, 2017 · Primary completion Dec 31, 2017
Drug: Propofol; Sevoflurane and 32 more · For: Hypotension
Sites: Nashville, Tennessee
- Anaesthetic Efficacy of 2% Mepivacaine Versus 4% Articaine With Symptomatic Irreversible PulpitisPivotal-lookingCompleted
Cairo UniversityAcademic, hospital or other
NCT04822415 · 330 participants · Start Dec 2014 · Primary completion Dec 2016
Drug: Mepivacaine; Articaine · For: Symptomatic Irreversible Pulpitis
University of AlgiersAcademic, hospital or other
NCT05908305 · 300 participants (planned) · Start Jun 10, 2023 · Primary completion Sep 29, 2023
Drug: articaine@ (4% 1:100000 epinephrine) dental anesthesia · For: Dental Pain and Sensation Disorder; Anesthesia, Local; Addiction, Opioid
- Articaine 4% Efficacy and Safety in Extraction and Pulpotomy of Primary Molars of Children Below the Age of Four YearsPivotal-lookingStatus unknown
Mahmoud Ahmed MahmoudAcademic, hospital or other
NCT05101785 · 292 participants (planned) · Start Nov 1, 2021 · Primary completion Sep 1, 2022
Drug: Lidocain hydrochloride 2 % with epinephrine; Articaine chloride 4% with epinephrine · For: Pain; Behavior
- A Safety Study of of AG-920 Sterile Topical Ophthalmic SolutionPivotal-lookingCompleted
American Genomics, LLCIndustry
NCT05501860 · 249 participants · Start Jul 30, 2022 · Primary completion Dec 7, 2022
Drug: AG-920; Placebo · For: Anesthesia, Local
Sites: Newport Beach, California; McAllen, Texas
- Uterovaginal Plexus Block With Articaine for Intrauterine Device Placement Patients Who Are Indicated for the Use of Copper IUD as a Contraceptive Method Will be Invited to Participate in This Research.Pivotal-lookingStatus unknown
Universidade do Vale do SapucaiAcademic, hospital or other
NCT05252117 · 240 participants (planned) · Start Feb 1, 2021 · Primary completion Apr 30, 2022
Drug: Articaine Hydrochloride 40 MG/ML; Mepivacaine · For: Contraception; IUD; Anesthesia, Local
Sites: Pouso Alegre, Brazil
- Cost-Effectiveness of Upfront Supplemental Anaesthesia in Symptomatic Irreversible PulpitisPivotal-lookingNot yet recruiting
Jamia Millia IslamiaAcademic, hospital or other
NCT07907120 · 234 participants (planned) · Start Oct 30, 2026 · Primary completion May 30, 2027
Drug: Inferior Alveolar Nerve Block With 2% Lidocaine With 1:80,000 Adrenaline; Upfront Buccal Infiltration With 4% Articaine With 1:100,000 Adrenaline and 1 more · For: Irreversible Pulpitis; Anesthesia, Local
Sites: New Delhi, India
- Efficacy Study of Articaine Versus Lidocaine as Supplemental Infiltration in Inflamed MolarsPivotal-lookingCompleted
University of MichiganAcademic, hospital or other
NCT01496846 · 201 participants · Start Sep 2011 · Primary completion Feb 2016
Drug: IANB Articaine; SUP Articaine and 1 more · For: Irreversible Pulpitis
Sites: Ann Arbor, Michigan
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective274
- hypoaesthesia40
- hypoaesthesia oral33
- pain22
- paraesthesia21
- injection site pain20
- electrocardiogram st segment elevation17
- swelling face17
- dizziness16
- discomfort15
- hypoxia15
- dyspnoea14
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 2 |
| 2005 | 5 |
| 2006 | 1 |
| 2007 | 2 |
| 2008 | 4 |
| 2009 | 1 |
| 2010 | 2 |
| 2011 | 2 |
| 2012 | 5 |
| 2013 | 4 |
| 2014 | 11 |
| 2015 | 20 |
| 2016 | 95 |
| 2017 | 166 |
| 2018 | 101 |
| 2019 | 22 |
| 2020 | 41 |
| 2021 | 13 |
| 2022 | 24 |
| 2023 | 32 |
| 2024 | 19 |
| 2025 | 20 |
| 2026 | 8 |
Recalls
1 FDA enforcement reports for this application.
May 2, 2019 · Class II · Terminated
Labeling: Not Elsewhere Classified. This recall has been initiated due to mislabeling. The printed carton used in manufacturing both batches contained text for both 2% Xylocaine DENTAL and Articadent DENTAL. Xylocaine...
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Adverse effects of articaine versus lidocaine in pediatric dentistry: a meta-analysis.
Li L, Sun DL · J Clin Pediatr Dent 2023 · Meta-Analysis, Systematic Review
- Transient neurological symptoms after spinal anesthesia.
Gozdemir M, Muslu B, Sert H, et al. · Clin Invest Med 2016 · Randomized Controlled Trial
- Efficacy of articaine formulations: quantitative reviews.
Paxton K, Thome DE · Dent Clin North Am 2010 · Comparative Study, Evaluation Study
- Articaine and lidocaine for maxillary infiltration anesthesia.
Vähätalo K, Antila H, Lehtinen R · Anesth Prog 1993 · Clinical Trial, Comparative Study
- Tramadol combined with local anesthesia for postoperative pain in third molar surgery.
Afat M, Gönül O, Satlmş T · BMC Oral Health 2025 · Randomized Controlled Trial
- Local anaesthesia for surgical extraction of mandibular third molars: a systematic review and network meta-analysis.
Yang F, Gao Y, Zhang L, et al. · Clin Oral Investig 2020 · Systematic Review, Network Meta-Analysis
Sponsor: Deproco
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.